« Return to News | Drug Sponsors | Technology Solutions

Charles River Labs to license EMD Millipore’s TrueSpike technology

Friday, March 2, 2012 06:00 AM

EMD Millipore, the life science division of Merck based in Billerica, Mass., will partner with Charles River Laboratories to exclusively license the TrueSpike technology, which reduces protein content of virus preparations and increases predictability of validation studies.

EMD and Charles River will collaborate to integrate the TrueSpike technology into viral clearance services provided by Charles River, designed to result in a more predictable and consistent study outcome for clients, ultimately helping to improve drug product safety. The companies’ combined expertise will result in higher purity virus preparations to help ensure validation success and regulatory compliance for biopharmaceutical manufacturers.

“This exclusive partnership with Charles River brings together their regulatory and viral clearance experience and our extensive knowledge of virus filtration and process engineering,” said Christophe Couturier, vice president of services and solutions, EMD. “The increased quality of virus preparations as delivered by TrueSpike technology will help ensure the success of our customers’ validation studies conducted by Charles River.”

TrueSpike technology enables removal of cell debris, DNA, and non-viral proteins from virus preparations used to validate biomanufacturing process virus clearance. Use of TrueSpike technology reduces the protein content of virus preparations used for validation studies up to 600 fold, which can lead to increased predictability of validation studies.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.